Treatment of atopic dermatitis with KAM-3008, a barrier-based, non-steroidal topical cream

References

• Williams HC. Clinical practice: atopic dermatitis. N Engl J Med. 2005;352:2314–24
   PubMed Web of Science ®Google Scholar
• Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999;103:125–38
   PubMed Web of Science ®Google Scholar
• Hudson TJ. Skin barrier function and allergic risk. Nat Genet. 2006;38:399–400
   PubMed Web of Science ®Google Scholar
• Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129:1892–908
   PubMed Web of Science ®Google Scholar
• Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside–inside–outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121:1337–43
   PubMed Web of Science ®Google Scholar
• Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441–6
   PubMed Web of Science ®Google Scholar
• Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002;47:198–208
   PubMed Web of Science ®Google Scholar
• Sugarman JL, Fluhr JW, Fowler AJ, et al. The objective severity assessment of atopic dermatitis score: an objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol. 2003;139:1417–22
   PubMed Web of Science ®Google Scholar
• Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132:751–62
   PubMed Web of Science ®Google Scholar
• Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol. 2008;17:1063–72
   PubMed Web of Science ®Google Scholar
• Werfel T. The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol. 2009;129:1878–91
   PubMed Web of Science ®Google Scholar
• Bieber T. The pro- and anti-inflammatory properties of human antigen-presenting cells expressing the high affinity receptor for IgE (Fc epsilon RI). Immunobiology. 2007;212:499–503
   PubMed Web of Science ®Google Scholar
• Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part I. J Eur Acad Dermatol Venereol. 2012;26:1045–60
   PubMed Web of Science ®Google Scholar
• Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15
   PubMed Web of Science ®Google Scholar
• Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol. 2006;54:818–23
   PubMed Web of Science ®Google Scholar
• Wojcikowski K, Stevenson L, Leach D, et al. Antioxidant capacity of 55 medicinal herbs traditionally used to treat the urinary system: a comparison using a sequential three-solvent extraction process. J Altern Complement Med. 2007;13:103–9
   PubMed Web of Science ®Google Scholar
• Ramalingam M, Yong-Ki P. Free radical scavenging activities of Cnidium officinale Makino and Ligusticum chuanxiong Hort. methanolic extracts. Pharmacogn Mag. 2010;6:323–30
   PubMed Web of Science ®Google Scholar
• Hei ZQ, Huang HQ, Tan HM, et al. Emodin inhibits dietary induced atherosclerosis by antioxidation and regulation of the sphingomyelin pathway in rabbits. Chin Med J (Engl). 2006;119:868–70
   PubMed Web of Science ®Google Scholar
• Kitano A, Saika S, Yamanaka O, et al. Emodin suppression of ocular surface inflammatory reaction. Invest Ophthalmol Vis Sci. 2007;48:5013–22
   PubMed Web of Science ®Google Scholar
• Li HL, Chen HL, Li H, et al. Regulatory effects of emodin on NF-kappaB activation and inflammatory cytokine expression in RAW 264.7 macrophages. Int J Mol Med. 2005;16:41–7
   PubMed Web of Science ®Google Scholar
• Ha MK, Song YH, Jeong SJ, et al. Emodin inhibits proinflammatory responses and inactivates histone deacetylase 1 in hypoxic rheumatoid synoviocytes. Biol Pharm Bull. 2011;34:1432–7
   PubMed Web of Science ®Google Scholar
• Matsui S, Matsumoto H, Sonoda Y, et al. Glycyrrhizin and related compounds down-regulate production of inflammatory chemokines IL-8 and eotaxin 1 in a human lung fibroblast cell line. Int Immunopharmacol. 2004;4:1633–44
   PubMed Web of Science ®Google Scholar
• Schröfelbauer B, Raffetseder J, Hauner M, et al. Glycyrrhizin, the main active compound in liquorice, attenuates pro-inflammatory responses by interfering with membrane-dependent receptor signaling. Biochem J. 2009;421:473–82
   PubMed Web of Science ®Google Scholar
• Asl MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res. 2008;22:709–24
   PubMed Web of Science ®Google Scholar
• Matsuda H, Tomohiro N, Ido Y, Kubo M. Anti-allergic effects of Cnidii Monnieri Fructus (dried fruits of Cnidium monnieri) and its major component, osthole. Biol Pharm Bull. 2002;25:809–12
   PubMed Web of Science ®Google Scholar
• Matsuda H, Ido Y, Hirata A, et al. Antipruritic effect of Cnidii Monnieri Fructus (fruits of Cnidium monnieri CUSSON). Biol Pharm Bull. 2002;25:260–3
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;92:44–7
   Google Scholar
• Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol. 2007;157:645–8
   PubMed Web of Science ®Google Scholar
• (No authors listed). Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186:23–31
   Google Scholar
• Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005;53:S50–8
   PubMed Web of Science ®Google Scholar
• Tempark T, Phatarakijnirund V, Chatproedprai S, et al. Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature. Endocrine. 2010;38:328–34
   PubMed Web of Science ®Google Scholar
• Herzog JL, Solomon JA, Draelos Z, et al. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis. J Drugs Dermatol. 2011;10:853–60
   PubMed Web of Science ®Google Scholar
• Abramovits W, Boguniewicz M, Adult Atopiclair Study Group. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol. 2006;5:236–44
   PubMedGoogle Scholar
• Veraldi S, De Micheli P, Schianchi R, Lunardon L. Treatment of pruritus in mild-to-moderate atopic dermatitis with a topical non-steroidal agent. J Drugs Dermatol. 2009;8:537–9
   PubMed Web of Science ®Google Scholar